The bull case for LivaNova: 2026 guidance calls for 9%-10% revenue growth and 14% adjusted EPS growth; OSA's 2027 launch could add upside. Click for more on LIVN stock.
LivaNova reported third quarter 2026 sales of US$393.1 million and net income of US$34.3 million, alongside nine month net income of US$165.2 million, while newly published CORE VNS data highlighted multi year seizure reduction and quality of life benefits in drug resistant epilepsy. The combination of stronger profitability and 36 month VNS Therapy outcomes, including a 76% median seizure reduction and 73% fewer seizure related hospitalizations, directly links LivaNova's earnings profile to...
Motley Fool Press Release.
The insider sold 1,650 shares but still retains nearly 8,000 shares.
GLOUCESTER, England, September 03, 2026--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present at the two following September healthcare conferences in New York City:
This is the newest page. Registered accounts read further back.